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Cartilage defects can impair the most elementary daily activities and, if not properly treated, can lead to the complete loss of
articular function. The limitations of standard treatments for cartilage repair have triggered the development of stem cell-based
therapies. In this scenario, the development of eﬃcient cell diﬀerentiation protocols and the design of proper biomaterial-based
supports to deliver cells to the injury site need to be addressed through basic and applied research to fully exploit the potential
of stem cells. Here, we discuss the use of microﬂuidics and bioprinting approaches for the translation of stem cell-based therapy
for cartilage repair in clinics. In particular, we will focus on the optimization of hydrogel-based materials to mimic the articular
cartilage triggered by their use as bioinks in 3D bioprinting applications, on the screening of biochemical and biophysical factors
through microﬂuidic devices to enhance stem cell chondrogenesis, and on the use of microﬂuidic technology to generate
implantable constructs with a complex geometry. Finally, we will describe some new bioprinting applications that pave the way
to the clinical use of stem cell-based therapies, such as scaﬀold-free bioprinting and the development of a 3D handheld device
for the in situ repair of cartilage defects.
1. Introduction
Cartilage defects, due to trauma or progressive joint degener-
ation, can impair the most elementary daily activities, such as
walking or running. Due to the limited self-repair ability of
cartilage, these lesions can easily evolve into osteoarthritis
(OA), leading to the complete loss of articular function and
to the subsequent need for joint replacement [1]. In the last
decades, the limitations of standard surgical treatments
for cartilage repair have triggered the development of
cell-based therapies. Autologous chondrocyte implantation
(ACI) has been the ﬁrst cell-based approach to treat cartilage
defects [2, 3], and more lately, stem cells have been proposed
as an alternative cell source for cell-based cartilage repair
[4, 5]. Among the various types of adult stem cells, mesen-
chymal stem cells derived from bone marrow (BMSCs)
have been widely used for cartilage applications due to their
well-demonstrated chondrogenic potential [6, 7]. Besides
BMSCs, more lately, adipose-derivedmesenchymal stem cells
(ADMSCs) obtained from diﬀerent adipose depots, including
knee infrapatellar fat pad, have gained growing interest as an
alternative cell source for cartilage repair [8–10].
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In the development of stem cell-based therapies for
tissue regeneration, bioprocessing optimization is required
to exploit the remarkable potential of stem cells. In particular,
eﬃcient cell diﬀerentiation protocols and the design of
proper biomaterial-based supports to deliver cells to the
injury site need to be addressed and overcome through basic
and applied research [11]. In this scenario, microﬂuidic
systems have attracted signiﬁcant interest implementing
platforms, in which the control of local environmental condi-
tions, including biochemical and biophysical parameters, is
exploited to study and direct stem cell fate [12, 13]. Indeed,
microﬂuidic technology enables the precise control over
ﬂuids at the microscale, thus allowing mimicking of the
natural cell microenvironment by continuous perfusion
culture or by creating chemical gradients [14]. Because of
these features, microﬂuidic devices can be eﬃciently used to
investigate the plethora of factors that guide stem cell
diﬀerentiation towards a speciﬁc cell lineage, testing several
conditions with minimal requirements in terms of cell num-
ber and amount of reagents to perform large experiments
[15]. So far, a suite of microﬂuidic devices has been devel-
oped to investigate the inﬂuence of both biochemical and
biophysical factors on stem cell diﬀerentiation in order to
outline new protocols for stem cell chondrogenesis [16–18].
Recently, microﬂuidic technology has also been used to
fabricate advanced systems for 3D bioprinting to produce
microchanneled scaﬀolds for the enhancement of nutrient
supply [19] or to encapsulate cells within microspheres or
ﬁbers [20–22]. 3D bioprinting is a novel research ﬁeld that
is showing excellent potential for the development of engi-
neered tissues, allowing the fabrication of heterogeneous
constructs with biochemical composition, mechanical prop-
erties, morphology, and structure comparable to those of
native tissues [23, 24]. As reported in several recent reviews
[23, 25–28], this technology has the potential to overcome
major problems related to the clinical translation of tissue
engineering products for cartilage repair, which has been so
far limited due to the poor results obtained in terms of
construct functionality. Indeed, cartilage properties are
determined by its complex architecture characterized by
anisotropic orientation of collagen ﬁbers and density gradi-
ents of chondrocytes, which even express slightly diﬀerent
phenotypes [29, 30]. 3D bioprinting, due to its ability to con-
trol material and cell positioning, appears as a promising
approach to replicate the complexity of zonal variability in
terms of cell densities and extracellular matrix (ECM) prop-
erties [31, 32]. Moreover, this technique oﬀers other advan-
tages, such as the possibility to reproduce subject-speciﬁc
geometry and topography starting from medical images to
create cell-laden constructs ﬁtting to the defect of the speciﬁc
patient [33].
In this review, we will describe how microﬂuidics and
bioprinting can provide diﬀerent insights in the ﬁeld of
mesenchymal stem cell-based cartilage repair and contribute
to the development of novel therapeutic strategies. Speciﬁ-
cally, since microﬂuidic and bioprinting technologies share
the use of hydrogel-based materials, in the ﬁrst section, we
will focus on the optimization of these materials to mimic
the composition and the mechanical properties of the
articular cartilage. We will then describe the use of microﬂui-
dic devices for the identiﬁcation of biochemical and biophys-
ical factors driving stem cell chondrogenesis that could be
implemented during the in vitro maturation of bioprinted
constructs. In addition, we will describe studies whereby
microﬂuidic and 3D bioprinting technologies have been
applied to generate implantable constructs with a complex
geometry. Finally, we will describe some new bioprinting
applications that pave the way to the clinical use of stem
cell-based therapies, such as scaﬀold-free bioprinting to gen-
erate clinically relevant constructs using 3D cell spheroids as
building blocks and the development of a 3D biofabrication
handheld device for the in situ repair of cartilage defects.
2. Microfluidics and Bioprinting to Trigger the
Translation of Cell-Based Therapy
2.1. Advancements in Hydrogel-Based Materials. In several
clinical applications, stem cells are directly injected into the
target tissue without any biomaterial carrier. This process
leads to limited stem cell engraftment at the treatment site,
mainly due to leakage of cell suspension during injection
[34]. Since the regeneration potential of stem cells is strongly
correlated with the number of cells retained at the lesion site,
improving stem cell engraftment is of utmost importance
[34]. The use of hydrogel carriers has been introduced to
overcome this limitation, by promoting cell retention at the
desired site and providing the implanted cells with a
microenvironment supporting cell viability and functions
[34, 35]. In the context of cartilage regeneration, hydrogels
have been widely applied, because of their numerous advan-
tages. These highly hydrated polymeric networks that can be
either natural or synthetic can be used for cell embedding as
well as for incorporating growth factors and ECM compo-
nents. Furthermore, hydrogels can be easily tailored in diﬀer-
ent geometries and, if properly designed, can provide the cells
with an environment similar to that of native cartilage [36, 37].
Because of their intrinsic features, hydrogels have been
applied as a 3D matrix for cell culture in microﬂuidic devices
[38] as well as bioinks for 3D bioprinting. In particular, their
increasing use in bioprinting has triggered the eﬀorts in the
optimization of hydrogel-based materials, in terms of com-
position, growth factor enrichment, and mechanical proper-
ties. Indeed, despite the promising advantages of bioprinting,
one of the major challenges is the absence of a material that
can be considered as the ideal bioink that satisﬁes all the
speciﬁc requirements, as described in a number of recent
reviews [39–42]. Regarding extrusion-based bioprinting pro-
cess, the bioink should present shear thinning behavior to
allow extrusion through the printer nozzle. At the same time,
the bioink should be characterized by quick shear recovery to
maintain the printed shape, showing adequate mechanical
properties to guarantee a proper environment for embedded
cells and long-term shape ﬁdelity, manipulation, and ease of
handling. Finally, the bioink should be biocompatible allow-
ing long-term culture of bioprinted cells. The bottleneck of
this technology is represented by the complexity to combine
rheological/mechanical properties and biological properties,
which are often mutually exclusive. To overcome this issue,
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there are two diﬀerent approaches: either to improve the bio-
compatibility of materials characterized by adequate printing
properties or to improve the printability of biocompatible
materials [43]. For instance, Armstrong et al. [44] have
formulated a new Pluronic-alginate multicomponent bioink
with BMSCs to generate bone and cartilage structures. In this
study, Pluronic was used as a sacriﬁcial template in order to
provide structural stability during printing, before chemical
crosslinking of alginate took place, as well as to generate
micropores and/or anisotropic microchannels in the con-
struct to increase nutrient diﬀusion after its removal.
Similarly, Kesti et al. [45] have improved the printability of
a photocrosslinkable methacrylated hyaluronan (HAMA)
by adding poly(N-isopropylacrylamide)-grafted hyaluronan
(HA-pNIPPAM), a thermoresponsive polymer with good
cytocompatibility used as a sacriﬁcial template. In this way,
the authors created a bioink in liquid state at room tempera-
ture that reticulates at body temperature. After thermal
gelation, the biopolymer was stabilized through free radical
polymerization of HAMA to achieve a long-term mechanical
stability. Finally, the HA-pNIPPAM was eluted through
medium washing at 4°C resulting in a glycosaminoglycan-
based scaﬀold. This procedure allowed printing scaﬀolds
with a diameter of 10mm and a height of 2.8mm, charac-
terized by high biocompatibility as shown by articular
chondrocyte viability.
The problem of the printability of soft biocompatible
materials was also addressed by Müller et al. [46] developing
a novel alginate sulfate-nanocellulose bioink for cartilage
applications. Notwithstanding the innate biocompatibility
of hydrogels derived from natural biopolymers such as
hyaluronic acid, chitosan, or alginate, the rheological behav-
ior of their solutions is often not suitable for 3D bioprinting.
To overcome this problem, Müller and colleagues increased
alginate viscosity through the addition of nanocellulose,
changing also the behavior from Newtonian-like to shear
thinning. The results of this study showed that articular
chondrocytes embedded in alginate sulfate-nanocellulose
were viable and synthesized type II collagen, proving the
suitability of the newly developed biomaterial for cell-based
cartilage repair. Composite bioinks combining nanoﬁbril-
lated cellulose (NFC) with alginate (NFC/A) and hyaluronic
acid (NFC/HA) were developed by Nguyen et al. [47]. In
particular, in the case of cartilage, the NFC mimics the bulk
collagen matrix, alginate simulates proteoglycans, and hya-
luronic acid substitutes for the hyaluronic acid found in the
native cartilage matrix. Noticeably, both alginate and nanoﬁ-
brillated cellulose are xeno-free and FDA-compliant mate-
rials and hence can be easily translated into clinical use.
The authors showed that both composite bioinks are print-
able; however, low proliferation and phenotypic changes
of printed human-derived-induced pluripotent stem cells
(iPSCs) were observed in the case of NFC/HA. On the other
hand, iPSCs printed in NFC/A produced a relevant amount
of hyaline-like cartilaginous tissue-rich and hyaline-like car-
tilaginous tissue-expressed chondrogenic markers, such as
aggrecan. Diﬀerently from the aforementioned study [47]
where the diﬀerent constituents of the bioink mix resembled
the diﬀerent components of the articular cartilage, the
approach developed by Levato et al. [48] to recapitulate the
cartilage composition and architecture is based on the intrin-
sic ability of primary cells to produce speciﬁc ECM. In fact,
these authors developed a zonal-like model using two diﬀer-
ent cell sources, chondrocyte progenitor cells (CPCs) and
BMSCs encapsulated in gelatin methacrylamide (GelMa)
hydrogels. By combining CPC- and MSC-laden bioinks, a
bioprinted model of the articular cartilage was generated,
consisting of deﬁned superﬁcial and deep regions, each with
distinct cellular and ECM composition. Noticeably, the
authors showed that their bioprinting method, which uses
Pluronic F-127 as sacriﬁcial ink to support GelMa during
the biofabrication process, allows fabricating clinically rele-
vant anatomical structures. However, to match the mechan-
ical properties of the articular cartilage, the bioprinted
material should undergo an extensive in vitro maturation
before implantation or reinforcement of a supporting mate-
rial. Indeed, hydrogels show low compressive stiﬀness result-
ing to becoming unsuitable for application in the fabrication
of load-bearing tissues. For this reason, several strategies
have been exploited to reinforce hydrogels using stiﬀer mate-
rials [27]. For instance, Daly et al. [49] engineered mechani-
cally reinforced hydrogels by codepositing soft bioinks, such
as agarose, alginate, and GelMa, with polycaprolactone
(PCL) ﬁlaments. In this way, the authors were able to obtain
BMSC-laden constructs with bulk compressive modulus sim-
ilar to the native articular cartilage. Noticeably, this approach
allowed at the same time enhancing the printability of soft
hydrogels and matching the mechanical properties needed
to withstand high mechanical loading within a joint environ-
ment, a result that is hardly achievable when using standard
hydrogels [23]. Another interesting work that focuses on
the reinforcement of bioinks was performed by Kang et al.
[50] who developed an integrated tissue-organ printer
(ITOP). This device includes a multiple cartridge system that
allows the deposition of cell-laden composite hydrogels in
combination with PCL polymer and an external sacriﬁcial
Pluronic F-127 hydrogel, which reinforces the material prop-
erties and supports the structure, respectively, during print-
ing. Through a 3-axial motorized stage system and an air
pressure-based controller, the ITOP is able to precisely regu-
late the dispensing volume of each material enabling the pro-
duction of constructs with structural integrity and complex
geometry. The promising results obtained using this system
to generate a human-scale ear-shaped bioprinted construct
indicate that this approach would be also suitable to print
clinically relevant constructs recapitulating the structures
and features of the native articular cartilage.
Despite the aforementioned approaches, the formulation
of the optimal bioink for cartilage tissue regeneration is still
to be achieved. Furthermore, the intrinsic complexity of the
native ECM is often neglected in 3D bioprinting experi-
ments. It is well known that the ECM microenvironment
plays a key role in directing the diﬀerentiation of stem cell
through receptor ligand interactions and mechanotransduc-
tion [51]. Hence, to successfully generate an instructive cell
niche, the tissue-speciﬁc cell-ECM interactions have to be
recapitulated. To this purpose, Pati and colleagues [52] have
recently proposed the use of a decellularized extracellular
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matrix (dECM) as bioink to maintain the complexity of the
native tissue (Figure 1). In particular, the articular cartilage
was decellularized, solubilized, combined with inferior turbi-
nate tissue-derived mesenchymal stromal cells (TMSCs), and
printed with a layer-by-layer technique using a PCL poly-
meric framework to support the structure during printing
and gelation. The obtained results showed that dECM scaf-
folds provided a biocompatible microenvironment for cell
proliferation and outperformed the control materials in
directing tissue-speciﬁc lineage commitment, as revealed by
the increased expression of chondrogenic markers. Remark-
ably, this study demonstrated that bioprinting with dECM
bioink is an attractive option that paves new ways for both
in vitro and in vivo tissue reconstruction. Additionally, the
developed material could be also particularly beneﬁcial in
the ﬁeld of in vitro cartilage models that currently use stan-
dard and nonspeciﬁc hydrogels, such as type I collagen and
ﬁbrin, as a 3Dmatrix for cell culture. For instance, the dECM
hydrogels, gelling at 37°C, could be easily used in microﬂuidic
models to better mimic the chondral environment and to
provide the cells with an instructive cell niche, representing
a signiﬁcant step forward in the development of biomimetic
chondral models. This study perfectly shows how the eﬀorts
in a research ﬁeld strongly related to the in vivo application,
such as 3D bioprinting, can lead to important advancements
in other apparently unrelated ﬁelds, such as in vitro biomi-
metic models, representing a perfect example of the conver-
gence between diﬀerent scientiﬁc areas.
2.2. Evaluation of Biochemical and Biophysical Factors. Stem
cell diﬀerentiation protocols exploit developmental signals to
instruct the cells and drive them towards a speciﬁc lineage.
The generation of models for the screening of multiple
growth factors is a crucial step to deﬁne diﬀerentiating
signals able to recapitulate in vitro the developmental pro-
cesses leading to chondrogenesis in vivo. Indeed, the identiﬁ-
cation of biochemical and biophysical parameters able to
trigger stem cell chondrogenesis can signiﬁcantly impact
the design of proper culture conditions for in vitro-generated
constructs in terms of medium composition as well as the
development of dynamic culture systems for the application
of biophysical stimuli. In this scenario, the results obtained
using in vitro models could be implemented during the
in vitro maturation of biofabricated constructs before their
implantation, in order to achieve the chondrogenic priming
of the engineered tissue. The deﬁnition of the most suitable
combination of diﬀerentiating signals often requires the
screening of several growth factor combinations, as well as
concentration ranges and timing, which easily results in a
complex experimental setup based on many levels of inter-
actions among multiple parameters. In this context, micro-
ﬂuidic technology oﬀers several advantages related to the
minimal number of cells required to test a high number
of experimental conditions and the use of very low amounts
of costly growth factors. Even more importantly, microﬂuidic
models feature an unprecedented spatial and temporal
control over the cell microenvironment. Indeed, the con-
trolled perfusion of the culture medium within microchan-
nels allows maintaining more uniform culture conditions
than standard static approaches, providing the stable sup-
ply of nutrients and growth factors as well as the removal
of waste products [13, 53]. Remarkably, controlled ﬂuid
ﬂow can also be exploited to automatically obtain gradients
of growth factors in the same microﬂuidic platform using
serial dilution generators (SDGs). This strategy was recently
applied by Occhetta et al. [16] who developed a microﬂuidic
platform implementing two diﬀerent SDGs to generate either
a wide range of concentrations of soluble factors (logarithmic
scale) or a narrower concentration window (linear scale)
(Figure 2(a)). This device was speciﬁcally designed to induce
the condensation of BMSCs within ﬂuidically connected
microchambers, enabling the formation of 3D micropellets
with uniform size and shape. Using this platform, the authors
were able at the same time to uniformly generate 3D cell
micropellets into deﬁned spatial conﬁgurations and culture
them under a continuous laminar ﬂow with deﬁned concen-
trations of transforming growth factor- (TGF-) β3 spanning
over four orders of magnitude. This screening led to identify
the lowest TGF-β3 concentration (0.1 ng/mL) as capable of
inducing chondrogenesis and maintaining the proliferative
ability of BMSCs, while the highest TGF-β3 concentration
(100 ng/mL) induced the disaggregation of the micropellets.
Noticeably, the results of this study demonstrated that the







Figure 1: Bioprinting of 3D constructs using a bioink based on a tissue-speciﬁc decellularized matrix. (a) Bioprinting process for the
obtainment of hybrid structures made of decellularized cartilage ECM (cdECM) and PCL for cartilage repair. Scale bar = 5mm. (b) SEM
images of the bioprinted construct. Scale bars = 400μm (adapted from [52]).
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occurring during the early stages of limb development, over-
coming one of the main limitations of other 3D models, such
as macropellets, which experience a reduction in cell number
over time due to the formation of a necrotic core [54]. The
use of SDGs has been also implemented in microﬂuidic plat-
forms designed and exploited to select the most suitable con-
centration and/or combination of growth factors to favor
articular chondrocyte proliferation, either in monolayer cul-
ture [55] or hydrogel-based culture [56]. The low number of
cells that can be obtained from patients’ biopsies is one of the
main limiting factors in ACI procedures, and hence, the opti-
mization of the protocol for chondrocyte expansion repre-
sents a crucial step to improve the outcome of this clinical
approach. Another strategy to overcome this limitation is
represented by combining MSCs and articular chondrocytes
as proposed by Higuera et al. [57] who developed an implant-
able screening device that allows the analysis of multiple
coculture conditions both in vitro and in vivo. The device
consists in a 3D-printed platform formed by arrays of micro-
to millimeter-scale wells that can be subcutaneously
implanted in nude mice to evaluate the inﬂuence of the cell
source on the accumulation of ECM. Because of this system,
the authors identiﬁed the optimal ratio of MSCs and articular
chondrocytes to achieve cartilaginous ECM deposition,
demonstrating the existence of optimal conditions for the
crosstalk between these two cell types.
Besides biochemical factors, the role of biophysical
factors as determinants in stem cell diﬀerentiation is also
gaining more and more attention. The development of a
biomimetic microenvironment allows a more precise study
of cell behavior in physiological-like conditions. In this
scenario, microﬂuidics has major advantages compared to
conventional 2D culture due to the possibility of replicating
some aspects of the in vivo 3D environment in terms of both
biochemical and physical stimuli. In this context, Rivera
and Baskaran [17] have developed a microﬂuidic device
TGF-훽3 concentration










































Figure 2: Microﬂuidic models for the screening of biochemical and biophysical factors. (a) Photograph of a microﬂuidic device including a
serial dilution generator to develop a gradient of growth factors and a 3D culture area for the generation and perfusion of 3D cell spheroids.
This device was exploited to generate a gradient of TGF-β3 and to identify the concentration able to induce type II collagen expression in
micropellets (adapted from [16]). (b) Schematic illustration of a microﬂuidic device with integrated electrospun nanoﬁbers to study the
inﬂuence of 3 diﬀerent ﬂow directions with respect to ﬁber orientation on stem cell chondrogenesis (adapted from [58]). (c) Schematic
representation of a microﬂuidic device for the development of the osteochondral interface. A system formed by two serpentines and a
central channel, respectively, ﬁlled with osteogenic medium (OM), chondrogenic medium (CM), and cell culture medium (M), allows the
generation of osteogenic and chondrogenic growth factor gradient to obtain spatially controlled diﬀerentiation of MSCs (adapted from [59]).
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to investigate simultaneously the inﬂuence of shear stress and
biomolecular gradients on BMSC alignment and chondro-
genesis. The 3-week exposure to TGF-β1 gradients via ﬂuid
ﬂow enhanced the formation of chondrogenic aggregates
with an increased cell elongation in ﬂow direction when
compared to a constant TGF-β1 concentration. The cellular
alignment was more evident in conﬂuent regions with
respect to nonconﬂuent regions demonstrating that both
shear stress and cell-cell contact inﬂuenced BMSC behavior.
Hence, exposing BMSCs to gradients of chondrogenic factors
and shear stress appears as a promising strategy to induce
chondrogenesis that can be implemented to generate engi-
neered tissues with superior features compared to standard
culture. An alternative microﬂuidic approach was exploited
to investigate the eﬀect of sequential mechanical and bio-
chemical stimuli on stem cell diﬀerentiation [18]. To this
purpose, a shear stimulation system controlled by a syringe
pump was used to apply a physiological shear stress of
1.5 Pa to a suspension of BMSCs ﬂowing through the tube.
Shear-stimulated BMSCs were then exposed to biochemi-
cal factors to determine if preconditioning BMSCs with a
mechanical stimulus could enhance their response to chon-
drogenic factors. Remarkably, this study highlighted that
BMSCs retain the memory of a single shear stimulation expe-
rience and that 3 weeks later, the commitment towards the
chondrogenic lineage was still superior in shear-stimulated
compared to nonstimulated cells, demonstrating the poten-
tial of this approach to inﬂuence stem cell fate and respon-
siveness to diﬀerentiating factors in a short timeframe.
Recent advances in microﬂuidic technology have also
allowed the incorporation of nanostructures in 3D microﬂui-
dic models to create a more biomimetic microenvironment
and understand the mechanotransduction dynamics modu-
lating stem cell fate. In particular, Zhong et al. [58] integrated
aligned nanoﬁbers obtained by electrospinning into a micro-
ﬂuidic platform to investigate the simultaneous role of
topographical cues and mechanical cues provided by ﬂuid
ﬂow (Figure 2(b)). The authors designed a microﬂuidic
device containing independent microchambers with multiple
orientations with respect to electrospun nanoﬁbers to allow
ﬂuid ﬂow to form diﬀerent angles with the nanoﬁbrous
substrate. The results showed that BMSCs preferentially
elongated along the nanoﬁber direction and that chondro-
genesis was improved by the presence of perpendicular ﬂow.
In this condition, the expression of type II collagen was
higher, whereas a signiﬁcant increase of type I collagen was
observed in cells under parallel ﬂow, demonstrating how
speciﬁc mechanotransduction signaling pathways regulate
BMSC diﬀerentiation by translating mechanical stimuli into
biochemical signals.
From the perspective of stem cell-based restoration of
the articular cartilage, the simultaneous triggering of eﬃ-
cient chondrogenesis and osteogenesis of stem cells in
the spatially deﬁned region of a 3D scaﬀold appears to
be a promising strategy to develop in vitro models for
the study of bone-cartilage crosstalk and, hence, to achieve
new strategies to improve the integration of the chondral
graft. In this context, the microﬂuidic technology provides
powerful tools to engineer interfacial tissues by exploiting
the intrinsic multidiﬀerentiation ability of stem cells. These
constructs can be either used as a disease model to investigate
the role of pathogenic signals that may aﬀect both cartilage
and the subchondral bone or to generate implantable con-
structs, representing a trait d’union between in vitro and
in vivo applications. Recently, Shi and colleagues [59] have
developed a microﬂuidic system able to generate gradients
of chondrogenic and osteogenic growth factors to steer
the spatially controlled chondrogenesis and osteogenesis of
ADMSCs embedded in the same hydrogel (Figure 2(c)). This
gradient-generating system includes a bottom layer consist-
ing of a PDMS pool ﬁlled with a stem cell-laden agarose
hydrogel covered with a microporous membrane and with
a top layer containing two lateral serpentine channels and
a central linear channel. To produce a biomimetic transi-
tional phase between osteogenic and chondrogenic zones, a
culture medium without any diﬀerentiation factors was
introduced into the central channel while chondrogenic
and osteogenic media were introduced into the two lateral
serpentines. After 25 days of culture, the spatially controlled
diﬀerentiation of stem cells into chondrocytes and osteo-
blasts was achieved and a region mimicking the bone-
cartilage interface was observed in the central region of
the hydrogel. The implementation of this type of
gradient-generating system in a more complex and clini-
cally relevant setup may pave the way to the in vitro engineer-
ing of interfacial tissues starting from a single cell source
seeded in a single biomaterial. This platform could also be
used to study the pathogenesis of diseases involving both
the articular cartilage and the subchondral bone, such as
OA. Indeed, the generated construct may represent a reliable
in vitro model of the osteochondral interface and the two
lateral serpentines could be used to generate a gradient of
pathogenic signals (e.g., proinﬂammatory cytokines) starting
from either the chondral or the bony side. A similar approach
has been used by Lin and colleagues [60] who developed a
microphysiological model of the osteochondral unit integrat-
ing a microﬂuidic system into a multichamber bioreactor.
This system was exploited to achieve spatially deﬁned chon-
drogenic or osteogenic diﬀerentiation of BMSCs loaded in a
methacrylated gelatin-based scaﬀold and to induce an OA-
like response through the targeted treatment of either the
chondral or the bony compartment with the proinﬂamma-
tory cytokine interleukin- (IL-) 1β. Using this approach, the
authors demonstrated that the exposure of the bony layer
to IL-1β resulted in a stronger catabolic response in the
chondral layer than the direct application of IL-1β to the
chondral component, indicating the active communication
between the two tissues. 3D bioprinting techniques have been
also exploited to generate anisotropic microscale multiphase
3D tissue models with potential impact in in vitro drug
testing, discovery, and development as reported by Gurkan
et al. [61]. In this study, the generation of an interfacial tissue
was achieved by printing BMSCs in nanoliter hydrogel
droplets encapsulating either bone morphogenetic protein-
(BMP-) 2 or TGF-β1 to drive their diﬀerentiation towards
diﬀerent lineages. The authors showed that phenotypic path-
way and network analysis can be performed using the geno-
mic expression data obtained from the model, demonstrating
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the potential of bioprinted anisotropic tissues as functional
in vitro 3D tissue models.
2.3. Improvement of Construct Architecture. In stem cell-
based cartilage applications, the use of hydrogel biomaterials
has been introduced to improve cell retention at the injury
site and to provide the implanted cells with a favorable
microenvironment. However, the use of bulk hydrogels has
some disadvantages including a high risk of ectopic chondro-
genesis and an ineﬃcient supply of oxygen and nutrients due
to the limited diﬀusion within hydrogels, which is often
restricted to 200μm and results in a necrotic core [62].
With advances in engineering technologies, such as soft
lithography and 3D bioprinting, microﬂuidic channels and
complex geometries have been engineered into hydrogels to
improve perfusion for the delivery of oxygen and nutrients
and removal of metabolic waste products for the embedded
cells [19, 63–67]. To obtain printable microﬂuidic channels,
Zhang and coworkers [19] have combined 3D bioprinting
and microﬂuidics for the generation of cell-embedding hol-
low ﬁlaments. In this study, coaxial nozzles were fabricated
using three ﬂuid-dispensing tips and assembling a feed tube,
an outer tube, and an inner tube. The feed tube was used to
deliver the alginate solution into the cavity formed between
the outer and inner tubes, while the CaCl2 crosslinking
solution was fed through the inner tube to create the hollow
ﬁlament. By modulating the ﬂow rate of alginate and CaCl2
solutions, the authors were able to tune the ratio between
the core diameter and the ﬁber diameter demonstrating the
great ﬂexibility of this technique. Chondrocyte progenitor
cells (CPCs) encapsulated within the hollow alginate ﬁbers
showed a high cell viability, proving the cytocompatibility
of this process. Noticeably, the expression of chondrogenic
markers was enhanced in encapsulated CPCs compared to
monolayer culture, indicating that alginate hollow ﬁlaments
provide an ideal environment for CPCs to diﬀerentiate and
carry out their cartilage-producing function. This strategy
allows fabricating 3D constructs loaded with progenitor cells,
yielding the viability and functionality of the cells seeded in
the central region, which usually have limited access to
nutrients and oxygen. Furthermore, as envisioned by the
authors, this approach can be implemented by printing
CPC spheroids between ﬁlaments and pumping a culture
medium through the hollow channels to promote the forma-
tion of a cartilage-speciﬁc matrix in tissue constructs with a
clinically relevant size. As aforementioned, the insuﬃcient
supply of nutrients and oxygen and the ineﬃcient waste
removal are major disadvantages when engineering in vitro
3D thick tissues. Embedding microﬂuidic networks within
3D hydrogel scaﬀolds represents a promising approach to
improve perfusion through thick tissues. Choi and coworkers
[65] have presented a strategy to control the distributions of
soluble chemicals within the scaﬀold with convective mass
transfer via microﬂuidic networks embedded within the
cell-seeded biomaterial. The authors exploited a lithographic
technique to generate functional microﬂuidic serpentines in
a calcium alginate hydrogel seeded with articular chondro-
cytes and characterized convective and diﬀusive solute
transfer, demonstrating that microﬂuidic channels enable
eﬃcient exchange of solutes with the bulk of the scaﬀold
and quantitative control of the soluble signals experienced
by the cells. This approach was also suitable to generate two
independent microﬂuidic networks in the same scaﬀold,
which could be particularly relevant in view of the adminis-
tration of diﬀerent growth factors to induce the spatially
controlled diﬀerentiation of stem cells seeded within the
same hydrogel to engineer interfacial tissues. A similar strat-
egy was adopted by Goldman and Barabino [66] to design
agarose constructs embedding a microﬂuidic serpentine in
order to enhance the viability of encapsulated articular
chondrocytes and the production of type II collagen and
glycosaminoglycans (Figure 3(a)). To this purpose, a PDMS
mold was used to generate a cell-laden agarose layer inte-
grating amicroﬂuidic serpentine (425× 425μm square cross-
section) that was then sealed against a planar slab of a
cell-laden agarose solution to complete the construct. This
study showed that the incorporation of a microﬂuidic
network in cell-laden agarose gels allows improving prolifer-
ation and ECM biosynthesis in tissue-engineered constructs
of relevant thickness (2.5mm and 5mm thick) compared to
bulk hydrogels.
Considering the exploitation of microﬂuidics as a biofab-
rication technology, interesting studies have been recently
published whereby microﬂuidics was used to produce 3D
scaﬀolds with uniform pore sizes [68, 69]. Speciﬁcally, Chung
et al. [68] used a microﬂuidic device including two concentric
tapered channels to generate bubbles enclosed within liquid
alginate droplets by pumping nitrogen gas and aqueous
alginate solution through the inner and the outer channels,
respectively. These bubbles spontaneously self-assembled
into a liquid foam that was then exposed to a CaCl2 solution
to induce alginate crosslinking and generate a solid foam.
This approach generated scaﬀolds with highly ordered and
interconnected pores with controlled size. In a following
study [69], the same group showed that this honeycomb
porous scaﬀold, which is characterized by a more ordered
structure than traditional alginate sponges, well supported
chondrocyte growth and phenotype maintenance demon-
strating that this highly organized scaﬀold prepared with an
economical microﬂuidic device holds potential for future
applications in the ﬁeld of cartilage tissue engineering.
The recent combination of 3D bioprinting with advanced
microﬂuidic printheads has recently found application in
many areas, leading to unprecedented advances in the
biofabrication of complex tissue constructs with high spatial
resolution [70]. In the context of cartilage repair, a system
based on two coaxial needles has been used to fabricate 3D
scaﬀolds via bioprinting composed of ECM biomimetic
hydrogels loaded with BMSCs (Figure 3(b)) [71]. In details,
the authors have developed a bioprinting system formed by
an external nozzle and an inner nozzle, dispensing CaCl2
and diﬀerent alginate-based hydrogel solutions, respectively.
In this way, as the two solutions came into contact, hydrogel
ﬁbers formed immediately at the tip of the inner nozzle
through a gelation process that allowed producing 3D
hydrogels with high resolution. After 3D bioprinting, the
constructs underwent a secondary UV crosslinking to
guarantee an eﬃcient bonding among ﬁbers belonging to
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adjacent layers determining the overall mechanical proper-
ties of the scaﬀolds. In particular, structures with a 5mm
height were printed depositing 50 layers with 100μm
thickness. 3D bioprinting experiments performed with
BMSCs showed that ionic crosslinking of alginate and UV
crosslinking were not detrimental to cell survival, proving
the biocompatibility of this approach.
Microﬂuidic technology has been also exploited to
achieve cell microencapsulation generating cell-laden micro-
gels in a high-throughput manner, as reported in several
recent reviews [72–74]. Remarkably, the use of these
microgels as building blocks that can be combined to obtain
relevant constructs oﬀers a major advantage with respect to
bulk hydrogels, since the large surface-to-volume ratio
promotes a more eﬃcient mass transport and enhanced
cell-matrix interactions. In the context of cartilage repair,
Li and colleagues have developed a simple and cheap
microﬂuidic device to encapsulate BMSCs in hydrogel-
based microspheres that can be crosslinked using visible light
[20] (Figure 3(c)). Speciﬁcally, the device was composed of an
ordinary pipette tip and two tubes connected to two syringes:
one containing a precursor hydrogel solution (aqueous
phase) and BMSCs and the other one loaded with oil (oily
phase). First, the pipette chamber was ﬁlled with oil, and
then, the dispersed hydrogel phase was pumped into the tube
at a constant rate to generate the microspheres through the
silicone tube. In this way, the authors were able to generate
microspheres with diﬀerent diameters (ranging from 300 to
600μm) by adjusting the ﬂow rate ratio between the aqueous
and the oily phase. The authors showed that BMSCs
encapsulated into the microspheres achieved a superior
chondrogenesis compared to the bulk hydrogel and that
microspheres could be injected into a cavity simulating a
























































Figure 3: Application of microﬂuidic and bioprinting technologies for the development of 3D cartilaginous constructs. (a) Schematic
representation of the custom-made dispensing coaxial system: calcium chloride ﬂows in the external nozzle while the bioink is supplied
through the inner one. Hydrogel ﬁbers form immediately at the tip of the inner nozzle when the two solutions come into contact.
Real-size neonatal ear can be obtained with a high printing resolution (≈100 μm). Scale bar = 10mm (3D bioprinting method reported in
[71]). (b) Fabrication process of a cell-laden agarose construct with an incorporated microﬂuidic serpentine to enhance oxygen and
nutrient transport (adapted from [66]). (c) Schematic diagram of chitosan microsphere production through a coaxial glass microcapillary
device. Each nanoﬁbrous microsphere is seeded with articular chondrocytes, and the deposition of newly generated ECM tightly bridges
the microspheres into a clinically relevant 3D construct (adapted from [21]). (d) Schematic representation of hydrogel microspheres with
encapsulated BMSCs produced by a simple syringe-based system. The obtained microspheres can be injected into the lesion site, as
demonstrated by the injection into an agarose gel model, which mimics an articular cartilage defect (adapted from [20]).
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thus proving the feasibility of intra-articular microsphere
injection and the clinical relevance of this approach.
Microﬂuidic technology has also been exploited as a
manufacturing technique for the preparation of microparti-
cles to generate clinically relevant 3D constructs, as reported
by Zhou and colleagues [21] (Figure 3(d)). Speciﬁcally, a
coaxial glass microcapillary device was assembled by round
and square glass capillaries, and chitosan and cyclohexane
solutions were ﬂown to generate an inner aqueous and an
outer oil phase, respectively. The generated emulsion was
collected in an alkaline solution to induce the gelation of
chitosan microspheres (ϕ 165–425μm), which were then
seeded with articular chondrocytes and cultured for 7 days.
The authors showed that this period was suﬃcient for
articular chondrocytes to tightly bridge chitosan micro-
spheres through ECM into bigger aggregates that were then
transferred into molds (ϕ 5mm, h 2mm) and cultured in
static conditions for 14 additional days. At the end of culture,
histological analysis showed that the spaces among the
microspheres were ﬁlled with cartilage-speciﬁc ECM rich in
glycosaminoglycans. Furthermore, the generated constructs
were able to withstand several compression cycles and
displayed a certain degree of elasticity, indicating that the
microspheres were tightly bonded together by the chon-
drocytes and the secreted ECM and demonstrating the
validity of this bottom-up approach for cartilage tissue
engineering applications.
2.4. New Approaches towards Clinical Practice. A particular
3D bioprinting approach to obtain highly organized con-
structs for tissue regeneration has been invented by Pro-
fessor Nakayama, using cell spheroids as building blocks
(Figure 4(a)) [75]. This innovative method belongs to the
biomaterial scaﬀold-free approach, for which exogenous
materials are not required. Diﬀerently from previous studies
whereby spheroids were manually assembled into 3D clini-
cally relevant constructs using cylindrical molds [76, 77],
in the “Kenzan Method,” a 3D bioprinter is used to roboti-
cally place cell spheroids in microneedles, which are used
as a temporary support during the fusion of spheroids. Each
array is composed by 160μm thick microneedles, which are
500μm distant from each other, and therefore, spheroids
should have a diameter of a hundred micrometers to get in
contact and form ECM in order to achieve a compact
construct. After the spheroid fusion, the constructs are
removed from the needle support and cultivated for the
postprinting maturation phase in which the holes formed
by the needle are resorbed due to their cell “healing”
capacity. Remarkably, although this technique diﬀers from
the standard approach of 3D bioprinting for the presence
of preformed cell spheroids and for the absence of
hydrogel-based materials, it represents a valid method to
produce constructs with a clinically relevant size, avoiding
potentially detrimental processes, which can occur during
standard 3D bioprinting procedures.
Another interesting approach that shares some funda-
mental principles with 3D bioprinting, such as the use of
living cells and biomaterials as building blocks, is repre-
sented by a 3D bioprinting pen, called “Biopen”, which
was developed by O’Connell et al. [78]. This new approach,
which represents one of the most relevant applications in
view of the clinical translation of bioprinting, was designed
to overcome the issues related to the traditional procedure
for tailoring implants to the anatomy of the defect. This
process involves the use of medical imaging data to create
implant design before the chondral repair procedure. How-
ever, such a method does not take into account the initial









Figure 4: 3D bioprinting approaches towards the clinical translation of cell-based therapies. (a) Kenzan Method, based on an automated
system for cell spheroid bioprinting, allows the deposition of 3D spheroids on a microneedle array as a support for the production of
scaﬀold-free 3D constructs [75]. (b) Schematic illustration of Biopen, a handheld device constituted of two bioink chambers, a collinear
nozzle, and a UV crosslinking source for the in situ deposition of cell-laden methacrylated hydrogels (adapted from [79]).
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of ﬁbrous tissue around the defect, thus varying its size
and shape. Diﬀerently from the standard bioprinting
approach, Biopen does not use a CT/MRI image for the
development of a digital model of the defect to direct
the deposition of cells and biomaterials, but the bioprint-
ing process is manually operated by the user in a direct
writing fashion during the surgical procedure. This feature
that represents the major diﬀerence between the Biopen
approach and standard 3D bioprinting is also the main
advantage of this device allowing the fabrication of con-
structs that perfectly ﬁt the shape and size of the chondral
defect. This handheld fabrication tool is composed of three
main components: an inner 3D-printed core that contains
two collinear ink chambers, a custom titanium extruder
nozzle, and a UV source. The extrusion process is con-
trolled by the user through a foot pedal-based pneumatic
system that allows depositing each ink individually and/
or simultaneously. In a preliminary phase, Biopen has
been tested in 2D deposition processes to verify the print-
ing stability and the ability to create compositional gradi-
ents controlling the relative extrusion rates of the two
chambers. The obtained results demonstrated the printing
capacities and consistency of fabricated objects using a
GelMa/HAMA hydrogel. In the latter phase, biological
experiments have been performed to evaluate the eﬀects of
the printing process on ADMSCs. In a subsequent work,
the same research group performed a pilot study to evaluate
the surgical applicability of Biopen to repair critical full
thickness chondral defects (ϕ 8mm) in an ovine model
[79]. Diﬀerently from the above-described device, the new
version of Biopen is characterized by a coaxial extrusion
system that allows depositing a biphasic hydrogel consti-
tuted by an inner “core” of GelMa-HAMA bioink laden with
ADMSCs from infrapatellar fat pad and an outer “shell” of
GelMa-HAMA bioink mixed with the photoinitiator
(Figure 4(b)). The presence of this outer shell warrants
photocuring of the construct during printing. The obtained
results showed that Biopen was able to deliver 3D-printed
scaﬀolds perfectly ﬁtting the shape and depth of the defect,
without causing any sign of inﬂammation or infection.
Moreover, constructs printed through Biopen showed a
higher amount of newly generated cartilage if compared
with both negative untreated controls and defects treated
by microfracture technique, evidencing chondrocyte colum-
nar alignment and maintenance of subchondral bone integ-
rity after 8 weeks from implantation. Promising results
were obtained also evaluating the mechanical properties
of Biopen-extruded scaﬀolds, which yielded values of instan-
taneous Young’s modulus, equilibrium modulus, and maxi-
mum stress similar to those of the native articular cartilage.
The promising outcomes reported in these studies [78, 79]
and the recent results regarding the optimization of the
bioprinting conditions to achieve high cell viability and
relevant structural stiﬀness [80] may pave the way to the
use of Biopen to build up mm- to cm-scale 3D structures.
More importantly, because of its ability to directly control
the deposition of biomaterials during the surgical process,
this device can represent an exciting advance in the trans-
lation of bioprinting into clinical practice, not only for
cartilage regeneration but also in other applications where
tissue regeneration is critical.
3. Outlook
Although stem cell-based therapies have emerged as a novel
treatment in cartilage-based repair, their success is often lim-
ited due to multiple factors, such as ineﬃcient diﬀerentiation
of stem cells towards the chondrogenic lineage and/or poor
stem cell engraftment and survival after transplantation. In
addition, an important aspect that is often neglected is that
stem cells are usually delivered to an inﬂamed environment
and, hence, have to face a plethora of catabolic signals that
may negatively aﬀect the outcome of cell-based approaches.
In this scenario, microﬂuidics can provide important
advances in the selection of biochemical and biophysical
factors able to direct the fate of stem cells that can be imple-
mented in new protocols for stem cell diﬀerentiation and in
the design of dynamic culture systems. It is also possible to
envision an exploitation of microﬂuidic models personalized
with patient-derived stem cells for the screening of the most
suitable diﬀerentiation protocol for each patient-speciﬁc
stem cell population. This would allow the optimization of
personalized diﬀerentiation protocols. Additionally, since
the use of growth factors during in vitro culture may pose
obstacles in the clinical translation of stem cell-based ther-
apy, the possibility to direct stem cell fate uniquely using
biophysical factors, such as shear stress, appears to be fasci-
nating. Microﬂuidic models hence represent an invaluable
tool to deﬁne the biophysical stimuli that should be used to
direct stem cells towards the chondrogenic lineage without
using growth factors. Furthermore, microﬂuidic devices can
be used to develop organotypic models of the whole articular
joint capable to recapitulate either a physiological or a path-
ological environment [81], perfectly matching the concept of
organs-on-chips for the study of tissue development, organ
physiology, and disease etiology [82, 83]. The models that
recapitulate the osteochondral unit on a single chip are a
striking evidence of the potential of microﬂuidics in this
context. Indeed, the comprehension of the inﬂammatory
events involving the articular cartilage and subchondral bone
may help in deﬁning complementary anti-inﬂammatory
treatments to promote the survival and the engraftment
of implanted stem cells. Recently, a new strategy to mold
and culture composite 3D cellular constructs featuring dif-
ferent cell types and/or biomaterials, with high spatial con-
trol in microﬂuidic channels, has been developed [84].
This technique allows obtaining a continuous gel-gel inter-
face, with no need for pillars to delimit the hydrogels, and
paves the way to the development of microﬂuidic models
including chondral and osseous compartments with highly
speciﬁc features in terms of cell and ECM composition.
Using this approach, it would be possible to combine a
miniaturized model of the articular cartilage with a minia-
turized model of the subchondral bone, including a calci-
ﬁed ECM, osteoblasts, osteoclasts, and endothelial cells
[85]. Bioprinting could be also used to generate microﬂui-
dic models of the articular joint, since it enables the print-
ing of multiple materials and diﬀerent types of living cells
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in a programmable manner with high spatial resolution,
and has proven to hold a great potential for fabricating
organs-on-a-chip recapitulating the intrinsic complexity
of the native tissue/organ [86, 87].
On the other hand, microﬂuidics-based 3D bioprinting
approaches could be used to overcome the problem of poor
cell engraftment at the lesion site, by transplanting stem
cells embedded in an ECM-mimicking environment. 3D
bioprinting is rapidly becoming a ﬁrst-choice approach
for several advanced applications in tissue engineering.
Despite the appealing advantages oﬀered by this technol-
ogy, such as rapid production of cellularized constructs
with high accuracy and repeatability independently of scaf-
fold geometry, a major ongoing challenge that still needs to
be addressed is related with bioink formulation. In fact, an
ideal bioink should provide, on one side, a proper matrix
for cell maturation, diﬀerentiation, and neomatrix synthesis
while still keeping, on the other side, a high printing reso-
lution. So far, this issue has been addressed only to a minor
extent and a continuous research is carried out to ﬁnd new
solutions. In the case of cartilage regeneration, 3D bioprint-
ing represents a suitable technology to recapitulate the
tissue structure in terms of chondrocytes and ECM organi-
zation. In particular, the complex zonal organization might
be reproduced in the future through the development of
more accurate systems for multimaterial deposition. Fur-
thermore, the formulation of bioinks should be reﬁned to
better promote stem cell diﬀerentiation towards the chon-
drogenic lineage with the synthesis of new polymers or with
the formulation of blends or composite bioinks that would
eventually result in enhanced quality of the neodeposited
matrix. Another major issue that must be overcome in
order to boost the translation of engineered constructs for
cartilage regeneration into the clinic is related to their poor
mechanical properties. In fact, native cartilage has a
Young’s modulus of around 700–800 kPa, which is between
one and two orders of magnitude higher compared to the
constructs obtained via 3D bioprinting. This is a key issue
that would require many eﬀorts to be overcome. A possible
solution may be found by employing more sophisticated
culture systems that may lead to more functional cartilage
tissue by providing controlled mechanical and biochemical
stimuli. However, then, we need to be sure that biofabri-
cated mature tissue will properly integrate with surround-
ing natural cartilage. So far, 3D bioprinting has already
demonstrated its capacity to build complex artiﬁcial struc-
tures. However, the future work must be focused on
enhancing the functionality of such constructs to prompt
applications in real clinical scenarios. Finally, in situ 3D
bioprinting can enable the achievement of thick tissues
directly into the lesion site in a one-step approach, by
translating bioprinters in the surgery room. Despite chal-
lenges, this computer-aided technology holds a great
potential since it would allow overcoming the need for
preshaping or reshaping of the scaﬀold based on the defect
geometry and achieving high precision in the deposition of
cells and biomaterials. Because of these features, we envi-
sion that in situ 3D bioprinting will produce signiﬁcant
advances in the regeneration of the entire articular units
or in the treatment of complex articulations, such as the
carpometacarpal joint.
Conflicts of Interest
The authors declare that they have no conﬂicts of interest.
Authors’ Contributions
Carlotta Mondadori and Valerio Luca Mainardi are equally
contributing authors.
Acknowledgments
This work was ﬁnanced by the Italian Ministry of Health
(Ricerca Finalizzata PE-2013-02356613) and by the National
Centre for Research and Development of Poland (Decision
no. Pol-Nor/202 132/68/2013).
References
[1] E. A. Makris, A. H. Gomoll, K. N. Malizos, J. C. Hu, and K. A.
Athanasiou, “Repair and tissue engineering techniques for
articular cartilage,” Nature Reviews Rheumatology, vol. 11,
no. 1, pp. 21–34, 2015.
[2] M. Brittberg, A. Lindahl, A. Nilsson, C. Ohlsson, O. Isaksson,
and L. Peterson, “Treatment of deep cartilage defects in the
knee with autologous chondrocyte transplantation,” The
New England Journal of Medicine, vol. 331, no. 14,
pp. 889–895, 1994.
[3] L. Peterson, H. S. Vasiliadis, M. Brittberg, and A. Lindahl,
“Autologous chondrocyte implantation: a long-term follow-
up,” The American Journal of Sports Medicine, vol. 38, no. 6,
pp. 1117–1124, 2010.
[4] A. Goldberg, K. Mitchell, J. Soans, L. Kim, and R. Zaidi,
“The use of mesenchymal stem cells for cartilage repair
and regeneration: a systematic review,” Journal of Orthopaedic
Surgery and Research, vol. 12, no. 1, p. 39, 2017.
[5] G. Filardo, F. Perdisa, A. Roﬃ, M. Marcacci, and E. Kon,
“Stem cells in articular cartilage regeneration,” Journal of
Orthopaedic Surgery and Research, vol. 11, no. 1, p. 42, 2016.
[6] H. Nejadnik, J. H. Hui, E. P. Feng Choong, B. C. Tai, and E. H.
Lee, “Autologous bone marrow-derived mesenchymal stem
cells versus autologous chondrocyte implantation: an observa-
tional cohort study,” The American Journal of Sports Medicine,
vol. 38, no. 6, pp. 1110–1116, 2010.
[7] S. Yamasaki, H. Mera, M. Itokazu, Y. Hashimoto, and
S. Wakitani, “Cartilage repair with autologous bone marrow
mesenchymal stem cell transplantation: review of preclinical
and clinical studies,” Cartilage, vol. 5, no. 4, pp. 196–202, 2014.
[8] F. Perdisa, N. Gostynska, A. Roﬃ, G. Filardo, M.Marcacci, and
E. Kon, “Adipose-derived mesenchymal stem cells for the
treatment of articular cartilage: a systematic review on preclin-
ical and clinical evidence,” Stem Cells International, vol. 2015,
Article ID 597652, 13 pages, 2015.
[9] S. Lopa, A. Colombini, D. Stanco, L. de Girolamo, V. Sansone,
and M. Moretti, “Donor-matched mesenchymal stem cells
from knee infrapatellar and subcutaneous adipose tissue of
osteoarthritic donors display diﬀerential chondrogenic and
osteogenic commitment,” European Cells & Materials, vol. 27,
pp. 298–311, 2014.
11Stem Cells International
[10] S. Lopa, A. Colombini, L. de Girolamo, V. Sansone, and
M. Moretti, “New strategies in cartilage tissue engineering for
osteoarthritic patients: infrapatellar fat pad as an alternative
source of progenitor cells,” Journal of Biomaterials and Tissue
Engineering, vol. 1, no. 1, pp. 40–48, 2011.
[11] D. M. Titmarsh, H. Chen, N. R. Glass, and J. J. Cooper-White,
“Concise review: microﬂuidic technology platforms: poised to
accelerate development and translation of stem cell-derived
therapies,” Stem Cells Translational Medicine, vol. 3, no. 1,
pp. 81–90, 2014.
[12] Q. Zhang and R. H. Austin, “Applications of microﬂuidics in
stem cell biology,” BioNanoScience, vol. 2, no. 4, pp. 277–
286, 2012.
[13] J. El-Ali, P. K. Sorger, and K. F. Jensen, “Cells on chips,”
Nature, vol. 442, no. 7101, pp. 403–411, 2006.
[14] G. M. Whitesides, “The origins and the future of microﬂui-
dics,” Nature, vol. 442, no. 7101, pp. 368–373, 2006.
[15] H. W. Wu, C. C. Lin, and G. B. Lee, “Stem cells in microﬂui-
dics,” Biomicroﬂuidics, vol. 5, no. 1, article 13401, 2011.
[16] P. Occhetta, M. Centola, B. Tonnarelli, A. Redaelli, I. Martin,
and M. Rasponi, “High-throughput microﬂuidic platform for
3D cultures of mesenchymal stem cells, towards engineering
developmental processes,” Scientiﬁc Reports, vol. 5, no. 1,
article 10288, 2015.
[17] A. L. Rivera and H. Baskaran, “The eﬀect of biomolecular
gradients on mesenchymal stem cell chondrogenesis under
shear stress,” Micromachines, vol. 6, no. 3, pp. 330–346, 2015.
[18] A. E. Adeniran-Catlett, E. Beguin, F. K. Bozal, and S. K.
Murthy, “Suspension-based diﬀerentiation of adult mesenchy-
mal stem cells toward chondrogenic lineage,” Connective
Tissue Research, vol. 57, no. 6, pp. 466–475, 2015.
[19] Y. Zhang, Y. Yu, H. Chen, and I. T. Ozbolat, “Characterization
of printable cellular micro-ﬂuidic channels for tissue engineer-
ing,” Biofabrication, vol. 5, no. 2, article 025004, 2013.
[20] F. Li, V. X. Truong, H. Thissen, J. E. Frith, and J. S. Forsythe,
“Microﬂuidic encapsulation of human mesenchymal stem
cells for articular cartilage tissue regeneration,” ACS Applied
Materials & Interfaces, vol. 9, no. 10, pp. 8589–8601, 2017.
[21] Y. Zhou, H. L. Gao, L. L. Shen et al., “Chitosan microspheres
with an extracellular matrix-mimicking nanoﬁbrous structure
as cell-carrier building blocks for bottom-up cartilage tissue
engineering,” Nanoscale, vol. 8, no. 1, pp. 309–317, 2016.
[22] B. G. Chung, K. H. Lee, A. Khademhosseini, and S. H. Lee,
“Microﬂuidic fabrication of microengineered hydrogels and
their application in tissue engineering,” Lab on a Chip,
vol. 12, no. 1, pp. 45–59, 2012.
[23] A. C. Daly, F. E. Freeman, T. Gonzalez-Fernandez, S. E.
Critchley, J. Nulty, and D. J. Kelly, “3D bioprinting for
cartilage and osteochondral tissue engineering,” Advanced
Healthcare Materials, vol. 6, no. 22, 2017.
[24] C. Mandrycky, Z.Wang, K. Kim, and D. H. Kim, “3D bioprint-
ing for engineering complex tissues,” Biotechnology Advances,
vol. 34, no. 4, pp. 422–434, 2016.
[25] G. O'Connell, J. M. Garcia, and A. A. Jamali, “3D bioprinting:
new directions in articular cartilage tissue engineering,” ACS
Biomaterials Science & Engineering, vol. 3, no. 11, pp. 2657–
2668, 2017.
[26] C. Di Bella, A. Fosang, D. M. Donati, G. G. Wallace, and
P. F. Choong, “3D bioprinting of cartilage for orthopedic
surgeons: reading between the lines,” Frontiers in Surgery,
vol. 2, p. 39, 2015.
[27] W. M. Groen, P. Diloksumpan, P. R. van Weeren, R. Levato,
and J. Malda, “From intricate to integrated: biofabrication of
articulating joints,” Journal of Orthopaedic Research, vol. 35,
no. 10, pp. 2089–2097, 2017.
[28] F. You, B. F. Eames, and X. Chen, “Application of
extrusion-based hydrogel bioprinting for cartilage tissue
engineering,” International Journal of Molecular Sciences,
vol. 18, no. 7, 2017.
[29] M. R. Buckley, J. P. Gleghorn, L. J. Bonassar, and I. Cohen,
“Mapping the depth dependence of shear properties in
articular cartilage,” Journal of Biomechanics, vol. 41, no. 11,
pp. 2430–2437, 2008.
[30] L. Bian, J. V. Fong, E. G. Lima et al., “Dynamic mechanical
loading enhances functional properties of tissue-engineered
cartilage using mature canine chondrocytes,” Tissue Engineer-
ing Part A, vol. 16, no. 5, pp. 1781–1790, 2010.
[31] T. J. Klein, J. Malda, R. L. Sah, and D. W. Hutmacher, “Tissue
engineering of articular cartilage with biomimetic zones,”
Tissue Engineering Part B: Reviews, vol. 15, no. 2, pp. 143–
157, 2009.
[32] W. Schuurman, T. J. Klein, W. J. A. Dhert, P. R. van Weeren,
D. W. Hutmacher, and J. Malda, “Cartilage regeneration using
zonal chondrocyte subpopulations: a promising approach or
an overcomplicated strategy?,” Journal of Tissue Engineering
and Regenerative Medicine, vol. 9, no. 6, pp. 669–678, 2015.
[33] C. T. Hung, E. G. Lima, R. L. Mauck et al., “Anatomically
shaped osteochondral constructs for articular cartilage repair,”
Journal of Biomechanics, vol. 36, no. 12, pp. 1853–1864, 2003.
[34] J. A. Burdick, R. L. Mauck, and S. Gerecht, “To serve and
protect: hydrogels to improve stem cell-based therapies,” Cell
Stem Cell, vol. 18, no. 1, pp. 13–15, 2016.
[35] L. M. Marquardt and S. C. Heilshorn, “Design of injectable
materials to improve stem cell transplantation,” Current Stem
Cell Reports, vol. 2, no. 3, pp. 207–220, 2016.
[36] Z. Izadifar, X. Chen, and W. Kulyk, “Strategic design and
fabrication of engineered scaﬀolds for articular cartilage
repair,” Journal of Functional Biomaterials, vol. 3, no. 4,
pp. 799–838, 2012.
[37] M. W. Tibbitt and K. S. Anseth, “Hydrogels as extracellular
matrix mimics for 3D cell culture,” Biotechnology and Bioengi-
neering, vol. 103, no. 4, pp. 655–663, 2009.
[38] X. J. Li, A. V. Valadez, P. Zuo, and Z. Nie, “Microﬂuidic 3D
cell culture: potential application for tissue-based bioassays,”
Bioanalysis, vol. 4, no. 12, pp. 1509–1525, 2012.
[39] A. Skardal and A. Atala, “Biomaterials for integration with 3-D
bioprinting,” Annals of Biomedical Engineering, vol. 43, no. 3,
pp. 730–746, 2015.
[40] M. Hospodiuk, M. Dey, D. Sosnoski, and I. T. Ozbolat, “The
bioink: a comprehensive review on bioprintable materials,”
Biotechnology Advances, vol. 35, no. 2, pp. 217–239, 2017.
[41] S. Ji and M. Guvendiren, “Recent advances in bioink design
for 3D bioprinting of tissues and organs,” Frontiers in Bio-
engineering and Biotechnology, vol. 5, p. 23, 2017.
[42] A. Panwar and L. P. Tan, “Current status of bioinks for
micro-extrusion-based 3D bioprinting,” Molecules, vol. 21,
no. 6, 2016.
[43] J. Visser, F. P. Melchels, J. E. Jeon et al., “Reinforcement of
hydrogels using three-dimensionally printed microﬁbres,”
Nature Communications, vol. 6, p. 6933, 2015.
[44] J. P. Armstrong, M. Burke, B. M. Carter, S. A. Davis, and A. W.
Perriman, “3D bioprinting using a templated porous bioink,”
12 Stem Cells International
Advanced Healthcare Materials, vol. 5, no. 14, pp. 1724–1730,
2016.
[45] M. Kesti, M. Müller, J. Becher et al., “A versatile bioink for
three-dimensional printing of cellular scaﬀolds based on
thermally and photo-triggered tandem gelation,” Acta Bioma-
terialia, vol. 11, pp. 162–172, 2015.
[46] M. Müller, E. Ozturk, O. Arlov, P. Gatenholm, and M. Zenobi-
Wong, “Alginate sulfate-nanocellulose bioinks for cartilage
bioprinting applications,” Annals of Biomedical Engineering,
vol. 45, no. 1, pp. 210–223, 2017.
[47] D. Nguyen, D. A. Hagg, A. Forsman et al., “Cartilage
tissue engineering by the 3D bioprinting of iPS cells in
a nanocellulose/alginate bioink,” Scientiﬁc Reports, vol. 7,
no. 1, p. 658, 2017.
[48] R. Levato, W. R. Webb, I. A. Otto et al., “The bio in the
ink: cartilage regeneration with bioprintable hydrogels and
articular cartilage-derived progenitor cells,” Acta Biomater-
ialia, vol. 61, pp. 41–53, 2017.
[49] A. C. Daly, S. E. Critchley, E. M. Rencsok, and D. J. Kelly, “A
comparison of diﬀerent bioinks for 3D bioprinting of ﬁbrocar-
tilage and hyaline cartilage,” Biofabrication, vol. 8, no. 4, article
045002, 2016.
[50] H. W. Kang, S. J. Lee, I. K. Ko, C. Kengla, J. J. Yoo, and
A. Atala, “A 3D bioprinting system to produce human-
scale tissue constructs with structural integrity,” Nature Bio-
technology, vol. 34, no. 3, pp. 312–319, 2016.
[51] F. Guilak, D. M. Cohen, B. T. Estes, J. M. Gimble, W. Liedtke,
and C. S. Chen, “Control of stem cell fate by physical interac-
tions with the extracellular matrix,” Cell Stem Cell, vol. 5, no. 1,
pp. 17–26, 2009.
[52] F. Pati, J. Jang, D. H. Ha et al., “Printing three-dimensional tis-
sue analogues with decellularized extracellular matrix bioink,”
Nature Communications, vol. 5, p. 3935, 2014.
[53] P. Occhetta, R. Visone, and M. Rasponi, “High-throughput
microﬂuidic platform for 3D cultures of mesenchymal stem
cells,” Methods in Molecular Biology, vol. 1612, pp. 303–
323, 2017.
[54] S. Lopa, A. Colombini, V. Sansone, F. W. Preis, and
M. Moretti, “Inﬂuence on chondrogenesis of human osteo-
arthritic chondrocytes in co-culture with donor-matched
mesenchymal stem cells from infrapatellar fat pad and sub-
cutaneous adipose tissue,” International Journal of Immu-
nopathology and Pharmacology, vol. 26, Supplement 1,
pp. 23–31, 2013.
[55] K. Tian, W. Zhong, Y. Zhang, B. Yin, W. Zhang, and H. Liu,
“Microﬂuidics-based optimization of neuroleukin-mediated
regulation of articular chondrocyte proliferation,” Molecular
Medicine Reports, vol. 13, no. 1, pp. 67–74, 2016.
[56] Y. Li, J. Qin, B. Lin, and W. Zhang, “The eﬀects of insulin-like
growth factor-1 and basic ﬁbroblast growth factor on the
proliferation of chondrocytes embedded in the collagen gel
using an integrated microﬂuidic device,” Tissue Engineering
Part C, Methods, vol. 16, no. 6, pp. 1267–1275, 2010.
[57] G. A. Higuera, J. A. Hendriks, J. van Dalum et al., “In vivo
screening of extracellular matrix components produced under
multiple experimental conditions implanted in one animal,”
Integrative Biology: Quantitative Biosciences from Nano to
Macro, vol. 5, no. 6, pp. 889–898, 2013.
[58] W. Zhong, W. Zhang, S. Wang, and J. Qin, “Regulation
of ﬁbrochondrogenesis of mesenchymal stem cells in an
integrated microﬂuidic platform embedded with biomimetic
nanoﬁbrous scaﬀolds,” PloS One, vol. 8, no. 4, article
e61283, 2013.
[59] X. Shi, J. Zhou, Y. Zhao, L. Li, and H. Wu, “Gradient-regulated
hydrogel for interface tissue engineering: steering simulta-
neous osteo/chondrogenesis of stem cells on a chip,” Advanced
Healthcare Materials, vol. 2, no. 6, pp. 846–853, 2013.
[60] H. Lin, T. P. Lozito, P. G. Alexander, R. Gottardi, and R. S.
Tuan, “Stem cell-based microphysiological osteochondral sys-
tem to model tissue response to interleukin-1β,” Molecular
Pharmaceutics, vol. 11, no. 7, pp. 2203–2212, 2014.
[61] U. A. Gurkan, R. El Assal, S. E. Yildiz et al., “Engineering
anisotropic biomimetic ﬁbrocartilage microenvironment by
bioprinting mesenchymal stem cells in nanoliter gel droplets,”
Molecular Pharmaceutics, vol. 11, no. 7, pp. 2151–2159, 2014.
[62] J. Malda, T. J. Klein, and Z. Upton, “The roles of hypoxia in the
in vitro engineering of tissues,” Tissue Engineering, vol. 13,
no. 9, pp. 2153–2162, 2007.
[63] W. Lee, V. Lee, S. Polio et al., “On-demand three-dimensional
freeform fabrication of multi-layered hydrogel scaﬀold with
ﬂuidic channels,” Biotechnology and Bioengineering, vol. 105,
no. 6, pp. 1178–1186, 2010.
[64] Y. Ling, J. Rubin, Y. Deng et al., “A cell-laden microﬂuidic
hydrogel,” Lab on a Chip, vol. 7, no. 6, pp. 756–762, 2007.
[65] N. W. Choi, M. Cabodi, B. Held, J. P. Gleghorn, L. J. Bonassar,
and A. D. Stroock, “Microﬂuidic scaﬀolds for tissue engineer-
ing,” Nature Materials, vol. 6, no. 11, pp. 908–915, 2007.
[66] S. M. Goldman and G. A. Barabino, “Cultivation of agarose-
based microﬂuidic hydrogel promotes the development of
large, full-thickness, tissue-engineered articular cartilage con-
structs,” Journal of Tissue Engineering and Regenerative
Medicine, vol. 11, no. 2, pp. 572–581, 2017.
[67] G. Y. Huang, L. H. Zhou, Q. C. Zhang et al., “Microﬂuidic
hydrogels for tissue engineering,” Biofabrication, vol. 3, no. 1,
article 012001, 2011.
[68] K. Y. Chung, N. C. Mishra, C. C. Wang, F. H. Lin, and K. H.
Lin, “Fabricating scaﬀolds by microﬂuidics,” Biomicroﬂuidics,
vol. 3, no. 2, article 022403, 2009.
[69] C. C. Wang, K. C. Yang, K. H. Lin, H. C. Liu, and F. H. Lin,
“A highly organized three-dimensional alginate scaﬀold for
cartilage tissue engineering prepared by microﬂuidic technol-
ogy,” Biomaterials, vol. 32, no. 29, pp. 7118–7126, 2011.
[70] X. Hou, Y. Shrike Zhang, G. Trujillo-de Santiago et al., “Inter-
play between materials and microﬂuidics,” Nature Reviews
Materials, vol. 2, no. 5, article 17016, 2017.
[71] M. Costantini, J. Idaszek, K. Szoke et al., “3D bioprinting of
BM-MSCs-loaded ECM biomimetic hydrogels for in vitro
neocartilage formation,” Biofabrication, vol. 8, no. 3, article
035002, 2016.
[72] D. M. Headen, G. Aubry, H. Lu, and A. J. Garcia, “Micro-
ﬂuidic-based generation of size-controlled, biofunctionalized
synthetic polymer microgels for cell encapsulation,” Advanced
Materials, vol. 26, no. 19, pp. 3003–3008, 2014.
[73] S. Selimovic, J. Oh, H. Bae, M. Dokmeci, and
A. Khademhosseini, “Microscale strategies for generating cell-
encapsulating hydrogels,” Polymers, vol. 4, no. 4, pp. 1554–
1579, 2012.
[74] W. Jiang, M. Li, Z. Chen, and K. W. Leong, “Cell-laden micro-
ﬂuidic microgels for tissue regeneration,” Lab on a Chip,
vol. 16, no. 23, pp. 4482–4506, 2016.
[75] N. I. Moldovan, N. Hibino, and K. Nakayama, “Principles of
the Kenzan Method for robotic cell spheroid-based three-
13Stem Cells International
dimensional bioprinting,” Tissue Engineering Part B, Reviews,
vol. 23, no. 3, pp. 237–244, 2017.
[76] D. Murata, S. Tokunaga, T. Tamura et al., “A preliminary
study of osteochondral regeneration using a scaﬀold-
free three-dimensional construct of porcine adipose tissue-
derived mesenchymal stem cells,” Journal of Orthopaedic
Surgery and Research, vol. 10, no. 1, p. 35, 2015.
[77] K. Ishihara, K. Nakayama, S. Akieda, S. Matsuda, and
Y. Iwamoto, “Simultaneous regeneration of full-thickness
cartilage and subchondral bone defects in vivo using a three-
dimensional scaﬀold-free autologous construct derived from
high-density bone marrow-derived mesenchymal stem cells,”
Journal of Orthopaedic Surgery and Research, vol. 9, no. 1,
p. 98, 2014.
[78] C. D. O’Connell, C. Di Bella, F. Thompson et al., “Develop-
ment of the Biopen: a handheld device for surgical printing
of adipose stem cells at a chondral wound site,” Biofabrication,
vol. 8, no. 1, article 015019, 2016.
[79] C. Di Bella, S. Duchi, C. D. O'Connell et al., “In situh and held
three-dimensional bioprinting for cartilage regeneration,”
Journal of Tissue Engineering and Regenerative Medicine, 2017.
[80] S. Duchi, C. Onofrillo, C. D. O'Connell et al., “Handheld co-
axial bioprinting: application to in situ surgical cartilage
repair,” Scientiﬁc Reports, vol. 7, no. 1, p. 5837, 2017.
[81] S. Bersini, C. Arrigoni, S. Lopa, M. Bongio, I. Martin, and
M. Moretti, “Engineered miniaturized models of musculoskel-
etal diseases,” Drug Discovery Today, vol. 21, no. 9, pp. 1429–
1436, 2016.
[82] S. N. Bhatia and D. E. Ingber, “Microﬂuidic organs-on-chips,”
Nature Biotechnology, vol. 32, no. 8, pp. 760–772, 2014.
[83] D. Huh, Y. S. Torisawa, G. A. Hamilton, H. J. Kim, and D. E.
Ingber, “Microengineered physiological biomimicry: organs-
on-chips,” Lab on a Chip, vol. 12, no. 12, pp. 2156–2164, 2012.
[84] G. S. Ugolini, R. Visone, A. Redaelli, M. Moretti, and
M. Rasponi, “Generating multicompartmental 3D biological
constructs interfaced through sequential injections in micro-
ﬂuidic devices,” Advanced Healthcare Materials, vol. 6,
no. 10, 2017.
[85] M. Bongio, S. Lopa, M. Gilardi, S. Bersini, and M. Moretti, “A
3D vascularized bone remodeling model combining osteo-
blasts and osteoclasts in a CaP nanoparticle-enriched matrix,”
Nanomedicine, vol. 11, no. 9, pp. 1073–1091, 2016.
[86] Q. Yang, Q. Lian, and F. Xu, “Perspective: Fabrication of
integrated organ-on-a-chip via bioprinting,” Biomicroﬂuidics,
vol. 11, no. 3, article 031301, 2017.
[87] H. Lee and D. W. Cho, “One-step fabrication of an organ-on-
a-chip with spatial heterogeneity using a 3D bioprinting tech-
nology,” Lab on a Chip, vol. 16, no. 14, pp. 2618–2625, 2016.
14 Stem Cells International
